Assembly and activation of the plasma kallikrein/kinin system: a new interpretation.

Understanding the importance and physiologic activity of the plasma kallikrein/kinin system (KKS) has been thwarted by the absence of an inclusive theory for its assembly and activation. The contact activation hypothesis describes the assembly and activation of this system in test tubes and disease states, but not under physiologic circumstances. Recent investigations have indicated a new cohesive hypothesis for understanding physiologic activation of this system. Prekallikrein (PK) and factor XI (FXI) through high molecular weight kininogen (HK) assemble on a co-localized, multiprotein receptor complex on endothelial cells that consists of at least cytokeratin 1 (CKI), gClqR, and urokinase plasminogen activator receptor (muPAR). When assembled on these proteins, prekallikrein becomes activated to kallikrein by the membrane-expressed enzyme prolylcarboxypeptidase (PRCP). Formed kallikrein then activates factor XII (FXII) for amplification of its activation and single chain urokinase. The plasma kallikrein/kinin system may serve as a physiologic counterbalance to the plasma renin angiotensin system (RAS) by lowering blood pressure and preventing thrombosis. Insights into the integrated role of these two systems may afford the development of novel therapeutic drugs to manage hypertension and thrombosis.

[1]  A. Schmaier,et al.  Kininogen-cytokeratin 1 interactions in endothelial cell biology. , 1999, Trends in cardiovascular medicine.

[2]  A. Schmaier,et al.  Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator* , 2002, The Journal of Biological Chemistry.

[3]  S. Reddigari,et al.  Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. , 1993, The Journal of biological chemistry.

[4]  J. Laragh,et al.  Linking the kallikrein and renin systems via activation of inactive renin: new data and a hypothesis. , 1978, The American journal of medicine.

[5]  A. Schmaier,et al.  Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. , 1996, Circulation.

[6]  A. Schmaier,et al.  Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. , 2002, Blood.

[7]  A. Schmaier,et al.  Thrombostatin Inhibits Cyclic Flow Variations in Stenosed Canine Coronary Arteries , 2001, Thrombosis and Haemostasis.

[8]  A. Schmaier,et al.  High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. , 1998, Blood.

[9]  D. Vaughan,et al.  Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin , 1997, Thrombosis and Haemostasis.

[10]  A. Schmaier,et al.  Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. G. Erdös,et al.  Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. , 1978, The Journal of biological chemistry.

[12]  A. Schmaier,et al.  Factor XI Assembly and Activation on Human Umbilical Vein Endothelial Cells in Culture , 2001, Thrombosis and Haemostasis.

[13]  E. G. Erdös,et al.  A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. , 1970, Biochimica et biophysica acta.

[14]  R. Kellner,et al.  Isolation and Characterization of the Kininogen-binding Protein p33 from Endothelial Cells , 1996, The Journal of Biological Chemistry.

[15]  A. Schmaier,et al.  Factor XII Does not Initiate Prekallikrein Activation on Endothelial Cells , 1998, Thrombosis and Haemostasis.

[16]  A. Schmaier The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. , 2002, The Journal of clinical investigation.

[17]  A. Schmaier,et al.  Mapping Binding Domains of Kininogens on Endothelial Cell Cytokeratin 1* , 1999, The Journal of Biological Chemistry.

[18]  A. Schmaier,et al.  Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. , 2001, American journal of physiology. Heart and circulatory physiology.

[19]  A. Schmaier,et al.  Identification of an endothelial cell binding site on kininogen domain D3. , 1995, The Journal of biological chemistry.

[20]  A. Schmaier,et al.  Activation of the Plasma Kallikrein/Kinin System on Cells: A Revised Hypothesis , 1999, Thrombosis and Haemostasis.

[21]  V. Gurewich,et al.  Assembly and Activation of the Intrinsic Fibrinolytic Pathway on the Surface of Human Endothelial Cells in Culture , 1995, Thrombosis and Haemostasis.

[22]  A. Schmaier,et al.  Assembly of High Molecular Weight Kininogen and Activation of Prekallikrein on Cell Matrix , 2001, Thrombosis and Haemostasis.

[23]  A. Schmaier,et al.  Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. , 2001, Blood.

[24]  A. Schmaier,et al.  Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5 (*) , 1995, The Journal of Biological Chemistry.

[25]  D. Normolle,et al.  Thrombostatin Inhibits Induced Canine Coronary Thrombosis , 1999, Thrombosis and Haemostasis.

[26]  E. Peerschke,et al.  Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Schmaier,et al.  Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. , 2002, Cardiovascular research.

[28]  T. Renné,et al.  High Molecular Weight Kininogen Utilizes Heparan Sulfate Proteoglycans for Accumulation on Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[29]  D. Vaughan,et al.  Prothrombotic effects of angiotensin. , 2000, Advances in internal medicine.

[30]  A. Schmaier,et al.  The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. , 1994, The Journal of biological chemistry.

[31]  Suchen L. Hong,et al.  Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. , 1980, Thrombosis research.